Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy
Cardiovascular Therapeutics, 05/02/2012Vaverkova H et al.
Switching to ezetimibe/simvastatin (EZE/SIMVA) 10/20 mg versus ROSUVA 10 mg provided superior lipid reductions in patients with/without type 2 diabetes mellitus (T2DM).
Patients (n = 618) at high risk for coronary vascular disease with elevated LDL–C ≥100 and ≤190 mg/dL despite use of statins were randomized 1:1 to double–blind EZE/SIMVA 10/20 mg or ROSUVA 10 mg for 6 weeks.
Patients were classified as having T2DM based on ≥1 of the following: diagnosis of T2DM, antidiabetic medication, or FPG ≥126 mg/dL.
This analysis evaluated percent changes from baseline in lipids among patients with (n = 182) and without T2DM (n = 434).
EZE/SIMVA was more effective than ROSUVA at lowering LDL–C, TC, non–HDL–C, and apo B in the overall study population and within both subgroups.
Numerically, greater between–treatment reductions in LDL–C, TC, non–HDL–C, and apo B were seen in patients with T2DM versus those without T2DM.
A significant interaction (P= 0.015) was seen for LDL–C indicating that patients with T2DM achieved larger between–group reductions versus those without T2DM.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.